Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Manchin is agreeing to a path forward!!

Sahil Kapur, 6-29-2022, "Senate Democrats see 'major progress' on Biden agenda bill, hope for July vote," NBC News, https://www.nbcnews.com/politics/congress/senate-democrats-see-major-progress-biden-agenda-bill-hope-july-vote-rcna36041, accessed 7-3-2022//cpd

WASHINGTON — Senate Democrats are close to a deal to lower prescription drug costs as part of a larger party-line package to advance a number of President Joe Biden's economic priorities, three sources familiar with the negotiations said.

Democrats plan to submit a "finalized agreement" on allowing Medicare to negotiate prices with pharmaceutical companies to a key Senate official "in the coming days" to see whether it complies with the chamber's strict budget rules, one of the sources said.

The source, who requested anonymity to discuss sensitive negotiations between Senate Majority Leader Chuck Schumer, D-N.Y., and Sen. Joe Manchin, D-W.Va., described the expected move as "major progress" that shows Democratic leadership wants to "move forward with a bill on the floor as early as next month."

There's no final deal on the broader bill, however, as the other major parts of the "reconciliation" package — energy and climate policy provisions and tax changes to raise revenue — are still being negotiated between Schumer and Manchin. Unless an agreement can be reached quickly, it would be difficult to pass the bill before a scheduled monthlong August recess.

Manchin’s office said Wednesday there is consensus and a path forward on drug pricing.

“Senator Manchin has long advocated for proposals that would lower prescription drug costs for seniors, and his support for this proposal has never been in question,” Manchin spokeswoman Sam Runyon said. “He’s glad that all 50 Democrats agree.”

What's in the drug pricing deal?

According to a summary of provisions obtained by NBC News, the emerging deal would empower Medicare to directly negotiate prescription drug prices starting next year to lower costs for consumers. It would cap out-of-pocket costs for Medicare patients at $2,000 per year and allow the cap to be broken up into monthly payments. It also would impose a new "inflation rebate" policy forcing drug companies to send money back to consumers if they raise prices above inflation.

In addition, the deal would add new incentives for drugmakers and insurers to limit drug price hikes, provide free vaccines for seniors, enhance premium and copay assistance for lower-income people and ensure the Department of Health and Human Services always negotiates for the maximum number of eligible drugs. And it would require negotiations to lower prices "if a drug company continues to block generic competition," the summary said.

Manchin rejected the House-passed Build Back Better Act in December but later indicated openness to a slimmed-down version that includes drug savings, climate and energy policy and higher taxes on upper earners and corporations. The Senate has not taken any action since then.

Sign in to recut, update, or save this card.